Just a summary of all the news articles that we could source from different places. A good way to make an investment decision is also to look at how actively the company is engaging with news sources to keep them in the news. In this day and age its critical to have a media presence.
Please consider a small donation if you think this website provides you with relevant information
| Date | Title | Source |
|---|---|---|
| 2024-03-07 12:1:28 pm | 3 Cancer-Fighting Biotech Stocks Showing Clinical Trial Promise | InvestorPlace |
| 2024-03-04 9:0:12 am | MorphoSys AG Unsponsored ADR (MOR) is a Great Momentum Stock: Should You Buy? | Zacks |
| 2024-02-15 9:0:5 am | What Makes MorphoSys AG Unsponsored ADR (MOR) a Strong Momentum Stock: Buy Now? | Zacks |
| 2024-02-13 10:15:49 pm | Q4 2023 Incyte Corp Earnings Call | Thomson Reuters StreetEvents |
| 2024-02-08 7:56:0 am | Biotech Stock Roundup: GILD, AMGN & BMY's Q4 Results, MOR Up on NVS Deal & More | Zacks |
| 2024-02-06 8:16:0 am | Novartis (NVS) to Buy MorphoSys & Add Late-Stage Oncology Drug | Zacks |
| 2024-02-06 1:30:0 am | MorphoSys to sell to Novartis for $2.9B, offload cancer drug to Incyte | BioPharma Dive |
| 2024-02-05 3:54:27 pm | Biotech Stock MorphoSys Catapults 56% As Novartis Agrees To Buy It For $2.9 Billion | Investor's Business Daily |
| 2024-02-05 3:35:46 pm | UPDATE 3-Novartis to acquire cancer-focused MorphoSys for $2.9 bln | Reuters |
Please consider a small donation if you think this website provides you with relevant information